Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10963473 | Vaccine | 2015 | 7 Pages |
Abstract
The aim of this non-randomized controlled trial was to compare time to progression (TTP), lymphoma-specific survival (LSS), and safety of an autologous vaccine (consisting of hydroxyapatite ceramic powder and Heat Shock Proteins purified from the dogs' tumors, HSPPCs-HA) plus chemotherapy versus chemotherapy alone in dogs with newly diagnosed, clinically advanced, histologically confirmed, multicentric indolent B-cell lymphoma. The vaccine was prepared from dogs' resected lymph nodes and administered as an intradermal injection. Forty-five client-owned dogs were enrolled: 20 dogs were treated with dose-intense chemotherapy, and 25 received concurrent immunotherapy. Both treatment arms were well tolerated, with no exacerbated toxicity in dogs also receiving the vaccine. TTP was significantly longer for dogs treated with chemo-immunotherapy versus those receiving chemotherapy only (median, 209 versus 85 days, respectively, PÂ =Â 0.015). LSS was not significantly different between groups: dogs treated with chemo-immunotherapy had a median survival of 349 days, and those treated with chemotherapy only had a median survival of 200 days (PÂ =Â 0.173). Among vaccinated dogs, those mounting an immune response had a significantly longer TTP and LSS than those with no detectable response (PÂ =Â 0.012 and PÂ =Â 0.003, respectively). Collectively these results demonstrate that vaccination with HSPPCs-HA may produce clinical benefits with no increased toxicity, thereby providing a strategy for enhancing chemotherapy in dogs with advanced indolent lymphoma.
Keywords
MZLLSSDLBCLMRDParRPLTDTHHspTTPimmunotherapypartial remissionprogressive diseasedelayed-type hypersensitivityPacked cell volumeMinimal residual diseasePeripheral bloodcomplete remissionTime to progressionWorld Health OrganizationDogFlow cytometrylactate dehydrogenaseLDHIndolent lymphomaDiffuse large B-cell lymphomaFollicular lymphomaMarginal zone lymphomabone marrowHydroxyapatiteHeat shock proteinHeat shock proteinsPlateletsPCVWHOLymph node
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
L. Marconato, D. Stefanello, S. Sabattini, S. Comazzi, F. Riondato, P. Laganga, P. Frayssinet, S. Pizzoni, N. Rouquet, L. Aresu,